Effect of dietary supplementation with ultramicronized palmitoylethanolamide in maintaining remission in cats with nonflea hypersensitivity dermatitis: a double-blind, multicentre, randomized, placebo-controlled study
Randomised controlled trialCats
- Design
- Randomised controlled trial
- Subjects
- 57 cats enrolled at 22 clinics in Italy. 25 cats completed the analysis (13 on the supplement, 12 on placebo).
- Dose used in the study
- 15 mg/kg once daily by mouth, as an ultramicronised oral suspension
- Duration
- A 28-day tapering course of methylprednisolone for all cats, then 8 weeks on the supplement or placebo, then 4 weeks of follow-up
- What was measured
- Time to relapse after the steroid was withdrawn; itch severity scores
What the authors reported
Mean time to relapse was 40.5 days in the supplement group against 22.2 days with placebo (P = 0.04). There were four adverse events in the supplement group and six with placebo, none classed as serious.
Limits of this study
Fewer than half of the enrolled cats completed the analysis. All cats received a steroid first, so the study measured delay of relapse, not an effect on its own. The P value is close to the threshold for a study of this size. The study was funded by Innovet Italia, which makes the product, and two authors declared links to the company.
Source
PubMed 31237065 · doi:10.1111/vde.12764
Entry checked against the full text at PubMed Central (PMC6852539) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.